Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.... [Read More]
A recent paper in Arthritis & Rheumatology opens up the possibility of a new research avenue to treat systemic sclerosis: dipeptidyl peptidase 4 (DPP4) inhibitors, a previously approved therapy for type 2 diabetes.1 Work in mouse models and on skin samples from systemic sclerosis patients suggests these drugs pose a promising area of future translational… [Read More]
Ultrasound may provide unique insights into the effects of immune checkpoint inhibitors on the human body beyond the immune system. Research suggests synovitis and inflammatory tendon involvement are commonly seen in patients with immune checkpoint inhibitor-induced inflammatory arthritis.... [Read More]
An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.... [Read More]
A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…... [Read More]
A 2019 study demonstrated the benefit of a newer drug class, PCSK9 inhibitors, to help lower cholesterol in patients with statin-associated immune-mediated necrotizing myopathy…... [Read More]
Recent research found inflammatory arthritis caused by immune checkpoint inhibitors (ICIs) may become a long-term disease, requiring rheumatology care and immunomodulatory treatment. Some patients experience active inflammatory arthritis years after ICI cessation…... [Read More]
In patients with active ankylosing spondylitis, IL-17 inhibitors have produced favorable responses, according to recent research…... [Read More]
Research into the disease-modifying effects of the novel cathepsin K inhibitor MIV-711 suggests it may be effective as a knee OA treatment. In OA patients using the treatment, the study documented statistically significant reductions in bone and cartilage progression…... [Read More]
SNOWMASS VILLAGE, COLO.—Janus kinase inhibitors—or Jakinibs—are a relatively new class of disease-modifying anti-rheumatic drugs (DMARDs) that perform well and have a safety profile comparable to biologics. This group of drugs was the subject of The New Frontier: Comparative Safety of JAK Inhibitors, a presentation given at the ACR Winter Symposium by Kevin L. Winthrop, MD,… [Read More]